Solid Biosciences Inc.
SLDBHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. With a market capitalization of $696.0M, it sits in small-cap territory. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
Market Cap
$696.0M
Beta
2.47
P/E (TTM)
—
P/E (Fwd)
-3.67
EPS (TTM)
$-1.92
EPS (Fwd)
$-1.93
ROE
-57.4%
ROA
-32.0%
Cash
$380.7M
Total Debt
$20.7M
Free CF
-$111.0M
52W Change
120.2%
Annual Financials
Cash vs Debt
With $380.7M in cash and $20.7M in debt, SLDB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$111.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -57.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $8.1M (2022) to $0 (2025), a 100% decline worth watching.
A beta of 2.47 means SLDB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, SLDB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Solid Biosciences Inc.'s trajectory.